G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

British Journal of Cancer

Volumn 98, Issue 3, 2008, Pages 523-528

  Bucher, N ^a,b   Britten, C D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell cycle; Checkpoint; Chk1; G2

Indexed keywords

7 HYDROXYSTAUROSPORINE; ATM PROTEIN; ATM PROTEIN INHIBITOR; ATR PROTEIN; ATR PROTEIN INHIBITOR; AZD 7762; BENZIMIDAZOLE; BLEOMYCIN; CAFFEINE; CBP 501; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; CHIR 124; CISPLATIN; DAUNORUBICIN; DIAZAPINOINDOLONE; ENZYME INHIBITOR; GEMCITABINE; GRANULATIMIDE DERIVATIVE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MACROCYCLIC COMPOUND; MITOGEN ACTIVATED PROTEIN KINASE 1; PD 0166285; PENTOXIFYLLINE; PF 00477736; PROTEIN INHIBITOR; PYRAZOLE DERIVATIVE; SMALL INTERFERING RNA; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 844;

ALLERGIC REACTION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DNA DAMAGE; DNA REPLICATION; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG DOSE ESCALATION; HUMAN; HYPERGLYCEMIA; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; CELL CYCLE; DNA DAMAGE; DNA REPAIR; G2 PHASE; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 38949147038     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604208     Document Type: Short Survey

References (50)

1. Anderes K, Blasina A, Chen E, Kornmann J, Kraynov E, Stempniak M, Register J, Ninkovic S, Fleur CL, O'Connor P (2006) Characterization of a novel and selective inhibitor of checkpoint kinase 1: breaching the tumor's last checkpoint defense against chemotherapeutic agents. Eur J Cancer Suppl 4: 115
2. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM (2003) Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278: 52572-52577
3. Ashwell S (2007) AZD7762, a novel potent and selective inhibitor of checkpoint kinases. Drug development track special session 2: New Drugs on the Horizon 2. AACR Annual Meeting 2007; 15 April 2007; AstraZeneca Research and Development: Waltham, MA
4. Bartek J, Falck J, Lukas J (2001) CHK2 kinase - a busy messenger. Nat Rev Mol Cell Biol 2: 877-886
5. Bartek J, Lukas C, Lukas J (2004) Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5: 792-804
6. Boutros R, Dozier C, Ducommun B (2006) The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 18(2): 185-191
7. Canman CE (2003) Checkpoint mediators: relaying signals from DNA strand breaks. Curr Biol 13: R488-R490
8. Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H, Rosenberg S, Fesik S, Zhang H (2003) Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2: 543-548
9. Conchon E, Anizon F, Aboab B, Prudhomme M (2007) Synthesis and biological activities of new checkpoint kinase 1 inhibitors structurally related to granulatimide. J Med Chem 50: 4669-4680
10. Falck J, Petrini J, Williams B, Lukas J, Bartek J (2002) The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 30: 290-294
11. Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, Hobson K, Savage K, Lukas J, Zhou BB, Bartek J, Khanna KK (2003) Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278: 14806-14811
12. Gordon M, Eder J, Mendelson D, Wasserman E, Sutherland W, Kawabe T, Shapiro G (2006) CBP501, a novel cell cycle G2 checkpoint abrogator. Preliminary results of the initial phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study in patients (pts) with advanced solid tumors. Eur J Cancer Suppl 4: 107. Abstract 346
13. Hallin M, Zhang C, Yan Z, Arango M, Chen E, Kraynov E, Anderes K (2007) PF-00477736 an inhibitor of Chk1 enhances the antitumor activity of docetaxel indicating a role for Chk1 in the mitotic spindle checkpoint. Am Assoc Cancer Res. Annual Meeting Proceedings. 14-18 April 2007; Los Angeles, CA. AACR: Philadelphia (PA). Abstract no. 4373
14. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816
15. Hashimoto O, Shinkawa M, Torimura T, Nakamura T, Selvendiran K, Sakamoto M, Koga H, Ueno T, Sata M (2006) Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 6: 292
16. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9159
17. Jack MT, Woo RA, Hirao A, Cheung A, Mak TW, Lee PW (2002) Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 99: 9825-9829
18. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
19. Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3: 513-519
20. Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK (2005) Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 23: 1875-1884
21. Lau C, Pardee A (1982) Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 79: 2942-2946
22. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14: 1448-1459
23. Liu S, Bekker-Jensen S, Mailand N, Lukas C, Bartek J, Lukas J (2006) Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol Cell Biol 26: 6056-6064
24. Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T, Sehested M, Lukas J, Bartek J (2001) DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res 61: 4990-4993
25. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, Lukas J (2000) Rapid destruction of human Cdc25A in response to DNA damage. Science 288: 1425-1429
26. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB (2005) MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 17: 37-48
27. Massague J (2004) G1 cell-cycle control and cancer. Nature 432: 298-306
28. Matthews D (2006) Dissecting the roles of Chk1 and Chk2 in mitotic catastrophe using chemical genetics. Eur J Cancer Suppl 4: 107
29. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, Robertson S, Murray L, Karnitz LM (2007) Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6: 104-110
30. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-189
31. Sancar A, Lindsey-Boltz LA, Unsal-Kaemaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85
32. Sha SK, Sato T, Kobayashi H, Ishigaki M, Yamamoto S, Sato H, Takada A, Nakajyo S, Mochizuki Y, Friedman JM, Cheng FC, Okura T, Kimura R, Kufe DW, Vonhoff DD, Kawabe T (2007) Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther 6: 147-153
33. Shah MA, Schwartz GK (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181
34. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770-1783
35. Stewart DJ, Hugenholtz H, DaSilva V, Benoit B, Richard M, Russell N, Maroun J, Verma S (1987) Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas. Semin Oncol 14: 110-115
36. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K, Motoyama N (2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 21: 5195-5205
37. Tao ZF, Li G, Tong Y, Chen Z, Merta P, Kovar P, Zhang H, Rosenberg SH, Sham HL, Sowin TJ, Lin NH (2007a) Synthesis and biological evaluation of 4′-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl) -biphenyl-4-ol as potent Chk1 inhibitors. Bioorg Med Chem Lett 17: 4308- 4315
38. Tao ZF, Wang L, Stewart KD, Chen Z, Gu W, Bui MH, Merta P, Zhang H, Kovar P, Johnson E, Park C, Judge R, Rosenberg S, Sowin T, Lin NH (2007b) Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J Med Chem 50: 1514-1527
39. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815
40. Tse AN, Carvajal R, Schwartz GK (2007a) Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13: 1955-1960
41. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S, Moler EJ, Ni ZJ, Lopes de Menezes DE, Hibner B, Gesner TG, Schwartz GK (2007b) CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 13: 591-602
42. Tse AN, Sheikh T, Schwartz G (2005) The Hsp90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17AAG) abrogates the G2/M DNA damage checkpoint and induces apoptosis selectively in p53-defective colon cancer cells by down-regulating both Chk1 and Wee1. Proc Am Assoc Cancer Res 46. Abstract 6159.
43. van den Bosch M, Bree RT, Lowndes NF (2003) The MRN complex: coordinating and mediating the response to broken chromosomes. EMBO Rep 4: 844-849
44. Watrin E, Peters JM (2006) Cohesin and DNA damage repair. Exp Cell Res 312: 2687-2693
45. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, Zhang H (2003) Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 278: 21767-21773
46. Xiao Z, Xue J, Sowin TJ, Zhang H (2006) Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 5: 1935-1943
47. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, Earnshaw WC, Gillespie DA (2007) Chk1 is required for spindle checkpoint function. Dev Cell 12: 247-260
48. Zhao H, Watkins J, Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 99: 14795-14800
49. Zou L, Cortez D, Elledge SJ (2002) Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. Genes Dev 16: 198-208
50. Zou L, Elledge SJ (2003) Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300: 1542-1548